3,227 results match your criteria: "Squamous Cell Carcinoma of the Urinary Bladder"
Vet Sci
November 2024
Institute of Animal Pathology, COMPATH, University of Bern, 3012 Bern, Switzerland.
Alterations of the gene and the resulting changes in the BRAF protein are one example of molecular cancer profiling in humans and dogs. We tested 227 samples of canine carcinomas from different anatomical sites (anal sac ( = 23), intestine ( = 21), liver ( = 21), lungs ( = 19), mammary gland ( = 20), nasal cavity ( = 21), oral epithelium ( = 18), ovary ( = 20), prostate ( = 21), thyroid gland ( = 21), urinary bladder ( = 22)) with two commercially available primary anti-BRAF antibodies (VE1 Ventana, VE1 Abcam). The immunohistochemical results were confirmed with droplet digital PCR (ddPCR).
View Article and Find Full Text PDFBMC Urol
November 2024
Department of Nephrology, Nanjing Pukou People's Hospital, No. 166, Shanghe Street, Nanjing, China.
Cells
October 2024
Department of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Minerva Urol Nephrol
November 2024
Institute for Health Research IdiPAZ, La Paz University Hospital, Madrid, Spain.
J Egypt Natl Canc Inst
November 2024
University of the Witwatersrand, Faculty of Health Sciences, School of Clinical Medicine, Department of Radiation Sciences, Division of Radiation Oncology, University of the Witwatersrand, Faculty of Health Sciences, School of Clinical Medicine, Department of Radiation Sciences, Division of Radiation Oncology, Johannesburg, South Africa.
Background: Bladder cancer (BCa) is one of the most common urological cancers and remains a leading cause of cancer-related mortality worldwide. Bladder cancer is associated with a range of risk factors, with smoking being one of the most significant contributors. In addition to smoking, exposure to certain chemicals, particularly aromatic amines found in industries such as dye, rubber, leather, and textiles, also increases the risk of bladder cancer.
View Article and Find Full Text PDFAsian J Endosc Surg
October 2024
Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan.
Introduction: In many cases of female radical cystectomy for bladder cancer, the procedure involves simultaneous removal of the uterus, fallopian tubes, ovaries, anterior vaginal wall, and urethra. After this procedure, rare complications like vaginal dehiscence and evisceration may occur. We herein describe this article surgical technique involving preservation of the distal anterior vaginal wall to maintain pelvic floor strength and retrograde resection of the proximal anterior vaginal wall.
View Article and Find Full Text PDFThorac Cancer
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Int J Mol Sci
October 2024
Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland.
The objective of our research was to determine the effects of xanthohumol (XN), a flavonoid isolated from hops (), and the anti-inflammatory drug niflumic acid (NA), separately and in combination with each other, on the proliferation of human cancer cells. Additionally, so as to understand the mechanism underlying the anticancer properties of the tested compounds, their effects on the biophysical parameters of a model membrane were assessed. The cells were incubated with XN and NA at various concentrations, either individually or in combination with each other.
View Article and Find Full Text PDFFront Oncol
October 2024
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
JCO Precis Oncol
October 2024
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Spinal Cord Ser Cases
September 2024
Neuro-Urology, Swiss Paraplegic Center, Nottwil, Switzerland.
Clin Genitourin Cancer
December 2024
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. Electronic address:
Clin Oncol (R Coll Radiol)
November 2024
Dept of Radiotherapy and Oncology, PGIMER, Chandigarh, India. Electronic address:
Ann Diagn Pathol
December 2024
Urology, Arnavutkoy State Hospital, Republic of Turkey Ministry of Health, Istanbul, Turkey.
Clin Genitourin Cancer
October 2024
Department of Urology, The George Washington University School of Medicine and Health Sciences, Washington, DC.
Abdom Radiol (NY)
December 2024
Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
J Urol
November 2024
Division of Urology, Western University, London, Ontario, Canada.
Virchows Arch
September 2024
Department of Pathology and Laboratory Medicine, Department of Surgery/Urology, Warren Alpert Medical School of Brown University, Lifespan Health, and The Legorreta Cancer Center at Brown University, Providence, RI, USA.
J Pak Med Assoc
June 2024
Department of Community Health Sciences, Peshawar Medical College, Riphah International University, Peshawar, Pakistan.
Bladder cancer is the ninth leading cause of death worldwide and 14th leading cause of death in Pakistan. The objective of this study was to determine the frequency of urothelial carcinoma in various age groups, its gender distribution, and grades. A total of 131 cases of urothelial carcinoma, received at Department of Pathology, Peshawar Medical College, Peshawar, between January 2017 to December 2022, were included in the study; of them 107 (81.
View Article and Find Full Text PDFUrol Oncol
October 2024
Department of Urology, Spitalzentrum Biel, Biel, Switzerland.
Clin Genitourin Cancer
October 2024
Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain; Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain.
Background: The PI3K/AKT/mTOR pathway is frequently altered at genomic level in metastatic urothelial carcinoma (mUC). Since mTOR is the last protein in the PI3K signaling cascade, it may have the largest impact on the pathway and has been a focus of targeted therapies. Sapanisertib (FTH-003/TAK-228) is an oral highly selective mTOR1 and mTOR2 inhibitor.
View Article and Find Full Text PDFAm Soc Clin Oncol Educ Book
June 2024
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
Eur Urol Focus
March 2024
Medical Oncology Department, Hospital de Sant Pau, Barcelona, Spain. Electronic address:
Abdom Radiol (NY)
August 2024
Department of Radiology, NYU Langone Health, New York, USA.